Breakthrough in Gene - editing: Disease - Agnostic Therapeutic Approach on the Horizon

At last week's WIRED Health summit, David Liu, a renowned Harvard biochemist and a pioneer in gene - editing, announced that his laboratory intends to disclose a singular gene - editing strategy later this year. This strategy, which he terms "disease - agnostic therapeutic gene editing," holds the potential to address a multitude of seemingly unrelated diseases.

Liu remarked to the Boston - based audience, "While it may appear somewhat extraordinary, there exists a sound molecular biology rationale underlying this possibility." However, he refrained from delving into the specifics at that time.

Currently, gene - editing therapies are in development for numerous rare and inherited genetic disorders. For instance, Casgevy, a gene - editing treatment, has been approved for commercial use in treating sickle cell disease and beta thalassemia, a related blood disorder. Earlier this year, a groundbreaking event occurred when KJ Muldoon, a newborn afflicted with a frequently fatal genetic disease causing ammonia to accumulate in his blood, was successfully treated using a customized gene - editing approach, marking a medical first.

These existing treatments operate by targeting specific mutations associated with the respective diseases. Nevertheless, their development can be exorbitantly costly, and they must be tailored to specific patient groups. In some cases, such as that of baby KJ, the patient population is extremely limited. KJ's condition, known as CPS1 deficiency, affects merely one in 1.3 million live births.

Liu envisions a future where a single gene - editing method could be applied across a diverse range of diseases, irrespective of the affected organ, tissue, or the genetic origin of the disease. He contends that such a streamlined approach is essential given the vast number of rare diseases. Collectively, the sheer quantity makes it impracticable to design individualized treatments for each one. Global Genes, an organization advocating for rare disease patients, estimates that there are at least 10,000 rare diseases globally, affecting over 400 million people.

Liu emphasized, "Genetic diseases, as a collective entity, are not as rare as commonly perceived. In fact, they are several times more prevalent than cancer or HIV/AIDS. There is an urgent need for methods that directly target the root causes of these genetic diseases."

Liu's laboratory has developed two novel approaches for combating rare diseases: base editing and prime editing. These next - generation iterations of the CRISPR technology are already being utilized in approximately two dozen clinical trials worldwide.

Base editing involves the use of laboratory - synthesized proteins capable of altering a single DNA base, or "letter," within a DNA sequence. For example, changing a cytosine (C) to a thymine (T). It can be likened to a pencil that corrects single - letter errors in the genetic code. The treatment administered to baby KJ employed a base editor.

Prime editing, on the other hand, functions analogous to a search - and - replace system for DNA. Unlike traditional CRISPR gene editing, which creates a double - stranded break in the DNA, prime editing enables precise additions, deletions, or substitutions without inducing such a break. Liu explained that a prime editor synthesizes a new DNA segment and coordinates the cell's repair processes, facilitating the replacement of the original DNA sequence with the new one. Essentially, it serves as a DNA word - processing tool.

At the WIRED Health event, Liu hinted that his laboratory has discovered a means to apply prime editing in a disease - agnostic fashion.

He stated, "Leveraging the search - and - replace capabilities of prime editing opens up the possibility that a single molecular composition - potentially, a single drug - could benefit a significantly larger number of patients compared to targeting diseases one mutation at a time. I believe this future for gene editing will multiply its impact manifold and, most crucially, enhance its accessibility to patients in need of these treatments."